Spots Global Cancer Trial Database for brca1
Every month we try and update this database with for brca1 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors | NCT04991480 | Advanced Cancer Metastatic Canc... Breast Cancer | ART4215 Talazoparib Niraparib | 18 Years - | Artios Pharma Ltd | |
| Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility | NCT02133703 | Breast Cancer Ovarian Cancer | Enhanced Intern... Internet DA Enhanced Print ... Print DA Inconclusive Re... | 21 Years - 75 Years | Georgetown University | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Adherence to Intensive Surveillance for Hereditary Breast Cancer | NCT00582803 | Breast Cancer | 25 Years - | Memorial Sloan Kettering Cancer Center | ||
| A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors | NCT04991480 | Advanced Cancer Metastatic Canc... Breast Cancer | ART4215 Talazoparib Niraparib | 18 Years - | Artios Pharma Ltd | |
| Analysis of Data From the Women's Contraceptive and Reproductive Experiences (CARE) Study | NCT00341159 | Breast Cancer | 35 Years - 64 Years | National Institutes of Health Clinical Center (CC) | ||
| Breast Cancer Risk Assessment Using Optical Breast Spectroscopy (OBS) | NCT00500383 | Breast Cancer | 25 Years - 60 Years | University Health Network, Toronto | ||
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Prostate Cancer Genetic Risk Evaluation and Screening Study | NCT05129605 | Prostatic Neopl... Prostate Cancer BRCA2 Mutation BRCA1 Mutation ATM Gene Mutati... MMR Mutation Lynch Syndrome Genetic Predisp... | Prostate cancer... | 35 Years - 74 Years | Massachusetts General Hospital | |
| Registry of Mastectomy for Breast Cancer Risk Reduction | NCT00555503 | Quality of Life Mastectomy Breast Neoplasm... Genetic Predisp... Adjustment Diso... | 18 Years - 70 Years | Georgetown University | ||
| Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer | NCT02557776 | Hereditary Brea... | Germline geneti... | 18 Years - | Lund University | |
| Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations | NCT02705846 | Prostate Cancer | Observation of ... | 18 Years - | Institute of Cancer Research, United Kingdom | |
| IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA) | NCT04012229 | Breast Cancer BRCA1 Mutation BRCA2 Mutation | BRCA mutation | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations | NCT02705846 | Prostate Cancer | Observation of ... | 18 Years - | Institute of Cancer Research, United Kingdom | |
| Genetic Education in BRCA Families | NCT03544983 | BRCA1 Mutation BRCA2 Mutation | Web + Streamlin... | 21 Years - 75 Years | Georgetown University | |
| IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA) | NCT04012229 | Breast Cancer BRCA1 Mutation BRCA2 Mutation | BRCA mutation | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| Analysis of Data From the Women's Contraceptive and Reproductive Experiences (CARE) Study | NCT00341159 | Breast Cancer | 35 Years - 64 Years | National Institutes of Health Clinical Center (CC) | ||
| Prophylactic Irradiation to the Contralateral Breast for BCAs Patients | NCT04960839 | Breast Cancer | Prophylactic co... | 30 Years - 70 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| COsegregation of VARiants in Panel of Genes | NCT01689584 | Gene Mutation-R... Genetic Predisp... | salivary kit | 18 Years - | Institut Curie | |
| Registry of Mastectomy for Breast Cancer Risk Reduction | NCT00555503 | Quality of Life Mastectomy Breast Neoplasm... Genetic Predisp... Adjustment Diso... | 18 Years - 70 Years | Georgetown University | ||
| A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer | NCT02797964 | Advanced Solid ... | SRA737 | 18 Years - | Sierra Oncology LLC - a GSK company | |
| A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations | NCT02950064 | Pancreatic Neop... Ovarian Neoplas... Breast Neoplasm... Prostatic Neopl... | BTP-114 | 18 Years - | Placon Therapeutics | |
| Prospective Multicentre Cohort Study PROREPAIR-B (mCRPC) | NCT03075735 | Prostate Cancer | 18 Years - 99 Years | Centro Nacional de Investigaciones Oncologicas CARLOS III | ||
| Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland | NCT01630226 | BRCA1 Mutation Breast Cancer I... | Neoadjuvant Cis... | 20 Years - 70 Years | Pomeranian Medical University Szczecin | |
| Adaptation to Living With a BRCA1/2 Mutation | NCT01866865 | Cancer Genetics | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Vinorelbine in Mesothelioma | NCT02139904 | Mesothelioma | Vinorelbine Active Symptom ... | 18 Years - | Wales Cancer Trials Unit | |
| A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes | NCT04171700 | Solid Tumor | Rucaparib | 18 Years - | pharmaand GmbH | |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | NCT04858334 | Pancreatic Acin... Pancreatic Aden... Pancreatic Squa... Resectable Panc... Resectable Panc... Resectable Panc... Resectable Panc... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Placebo Adminis... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | NCT01482715 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Advanced Solid ... | Rucaparib | 18 Years - | pharmaand GmbH | |
| Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations | NCT02705846 | Prostate Cancer | Observation of ... | 18 Years - | Institute of Cancer Research, United Kingdom | |
| Breast Cancer Risk Assessment Using Optical Breast Spectroscopy (OBS) | NCT00500383 | Breast Cancer | 25 Years - 60 Years | University Health Network, Toronto | ||
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Vinorelbine in Mesothelioma | NCT02139904 | Mesothelioma | Vinorelbine Active Symptom ... | 18 Years - | Wales Cancer Trials Unit | |
| Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | NCT02393794 | Triple-Negative... Breast Cancer | Romidepsin Cisplatin Nivolumab | 18 Years - | University of Kansas Medical Center | |
| Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations | NCT00823654 | Breast Cancer | Blood draw and ... Blood draw and ... | 18 Years - 44 Years | Memorial Sloan Kettering Cancer Center | |
| Prospective Multicentre Cohort Study PROREPAIR-B (mCRPC) | NCT03075735 | Prostate Cancer | 18 Years - 99 Years | Centro Nacional de Investigaciones Oncologicas CARLOS III | ||
| A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer | NCT02797964 | Advanced Solid ... | SRA737 | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families | NCT03119285 | Ovarian Cancer | 18 Years - | University of Washington | ||
| Is it Feasible?: Self-Affirmation for Hereditary Breast and Ovarian Cancer Genetic Counseling | NCT03225170 | Breast Cancer | Self Affirmatio... Control | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Prophylactic Irradiation to the Contralateral Breast for BCAs Patients | NCT04960839 | Breast Cancer | Prophylactic co... | 30 Years - 70 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Pancreas Registry and High Risk Registry | NCT02775461 | Pancreas Cancer Pancreatitis Chronic Pancrea... Pancreatic Cyst Family History ... Genetic Mutatio... | 18 Years - | Icahn School of Medicine at Mount Sinai | ||
| Prophylactic Irradiation to the Contralateral Breast for BCAs Patients | NCT04960839 | Breast Cancer | Prophylactic co... | 30 Years - 70 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Prospective Multicentre Cohort Study PROREPAIR-B (mCRPC) | NCT03075735 | Prostate Cancer | 18 Years - 99 Years | Centro Nacional de Investigaciones Oncologicas CARLOS III | ||
| IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA) | NCT04012229 | Breast Cancer BRCA1 Mutation BRCA2 Mutation | BRCA mutation | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| The Genetic Education for Men Trial: Web-Based Education vs. Standard Care | NCT02957981 | Prostate Carcin... Breast Neoplasm Pancreatic Canc... BRCA1 Mutation BRCA2 Mutation | Web-based Couns... Standard Care | 25 Years - 70 Years | Georgetown University | |
| Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland | NCT01630226 | BRCA1 Mutation Breast Cancer I... | Neoadjuvant Cis... | 20 Years - 70 Years | Pomeranian Medical University Szczecin | |
| Genetic Testing for Men With Metastatic Prostate Cancer | NCT03503097 | Metastatic Pros... Stage IV Prosta... Stage IVB Prost... | Biospecimen Col... Genetic Counsel... Genetic Testing Laboratory Biom... Questionnaire | 18 Years - | University of Washington | |
| The Genetic Education for Men Trial: Web-Based Education vs. Standard Care | NCT02957981 | Prostate Carcin... Breast Neoplasm Pancreatic Canc... BRCA1 Mutation BRCA2 Mutation | Web-based Couns... Standard Care | 25 Years - 70 Years | Georgetown University | |
| Open-Label,Non-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients | NCT01611727 | BRCA1 Mutation Metastatic Brea... | Cisplatin | 18 Years - | Pomeranian Medical University Szczecin | |
| Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans | NCT01374685 | Ovarian Neoplas... Cancer Genetics Breast Cancer | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer | NCT00261456 | Prostate Cancer... | PSA test Prostate Biopsy | 40 Years - 69 Years | Institute of Cancer Research, United Kingdom | |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | NCT04858334 | Pancreatic Acin... Pancreatic Aden... Pancreatic Squa... Resectable Panc... Resectable Panc... Resectable Panc... Resectable Panc... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Placebo Adminis... | 18 Years - | National Cancer Institute (NCI) | |
| Vinorelbine in Mesothelioma | NCT02139904 | Mesothelioma | Vinorelbine Active Symptom ... | 18 Years - | Wales Cancer Trials Unit | |
| Adherence to Intensive Surveillance for Hereditary Breast Cancer | NCT00582803 | Breast Cancer | 25 Years - | Memorial Sloan Kettering Cancer Center | ||
| A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer | NCT02163694 | Metastatic Brea... | Veliparib Place... Veliparib Carboplatin Paclitaxel | 18 Years - | AbbVie | |
| Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families | NCT03119285 | Ovarian Cancer | 18 Years - | University of Washington | ||
| Radical Fimbriectomy for Young BRCA Mutation Carriers | NCT01608074 | BRCA1 Mutation BRCA2 Mutation Hereditary Brea... | Radical fimbrie... Histopathology ... | 35 Years - | Centre Oscar Lambret | |
| Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer | NCT00590109 | Breast Cancer | Blood test Questionnaire | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers | NCT01022333 | Breast Cancer | Diindolylmethan... | 25 Years - 45 Years | Women's College Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
